MEDICINE DETAILS
Voxzogo
Active ingredient: Vosoritide
Neutral reference profile for an independent medicine-access consultancy enquiry about Voxzogo (Vosoritide). No medicine is offered for sale.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Voxzogo used for?
Voxzogo (vosoritide) is an FGFR3 inhibitor indicated to treat achondroplasia in patients 2 years and older whose epiphyses (growth plates of the bones) are not yet closed.
It is available in powder form, containing 0.4 mg, 0.56 mg, or 1.2 mg powder vosoritide.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Voxzogo identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
0.4 mg · 10 powder and solvent sets Catalogue organisation: BIOMARIN INTERNATIONAL LIMITED
-
0.56 mg · 10 powder and solvent sets Catalogue organisation: BIOMARIN INTERNATIONAL LIMITED
-
1.2 mg · 10 powder and solvent sets Catalogue organisation: BIOMARIN INTERNATIONAL LIMITED
OFFICIAL SOURCES
Check the Voxzogo record at an official source.
Search for “Voxzogo” or “Vosoritide”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Voxzogo.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Voxzogo
01What is Voxzogo?+
This directory record associates the brand name Voxzogo with the active ingredient Vosoritide. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Voxzogo strengths and packs are recorded?+
The catalogue currently shows: 0.4 mg · 10 powder and solvent sets; 0.56 mg · 10 powder and solvent sets; 1.2 mg · 10 powder and solvent sets. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Voxzogo?+
Catalogue records currently name: BIOMARIN INTERNATIONAL LIMITED. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?+
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Voxzogo?+
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Voxzogo, payment request, stock guarantee or binding offer.
06Can I buy Voxzogo from this website?+
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.